Phase 2 Study of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

November 9, 2023

Primary Completion Date

July 21, 2026

Study Completion Date

August 18, 2026

Conditions
Atopic Dermatitis
Interventions
DRUG

SAR444656 (KT-474)

Oral Tablet

DRUG

Placebo

Oral Tablet

Trial Locations (37)

13353

Investigational Site Number : 2760001, Berlin

15213

UPMC Montefiore- Site Number : 8400006, Pittsburgh

15355

Investigational Site Number : 4100001, Ansan-si

21614

Investigational Site Number : 2760002, Buxtehude

33024

Encore Medical Research - 6600 Taft St- Site Number : 8400004, Hollywood

33122

Revival Research - Doral- Site Number : 8400007, Doral

33162

Sullivan Dermatology- Site Number : 8400001, Miami

33331

Encore Medical Research - Weston- Site Number : 8400008, Weston

33436

Encore Medical Research of Boynton Beach- Site Number : 8400002, Boynton Beach

42897

Investigational Site Number : 2760006, Remscheid

44791

Investigational Site Number : 2760003, Bochum

48126

Wayne Health - Dearborn- Site Number : 8400009, Dearborn

60590

Investigational Site Number : 2760008, Frankfurt am Main

69120

Investigational Site Number : 2760007, Heidelberg

80337

Investigational Site Number : 2760009, Munich

85255

Clear Dermatology & Aesthetics Center- Site Number : 8400003, Scottsdale

330721

Investigational Site Number : 4100002, Cheonan-si

33176-1032

ARA Professionals- Site Number : 8400017, Miami

75010-4632

ACRC Trials - Carrollton - Hunt - PPDS- Site Number : 8400012, Carrollton

702 00

Investigational Site Number : 2030002, Ostrava

530 02

Investigational Site Number : 2030001, Pardubice

150 00

Investigational Site Number : 2030003, Prague

06847

Investigational Site Number : 2760010, Dessau

564 29

Investigational Site Number : 3000001, Pavlos Melas

546 43

Investigational Site Number : 3000002, Thessaloniki

33-100

Investigational Site Number : 6160006, Tarnów

50-449

Investigational Site Number : 6160012, Wroclaw

50-566

Investigational Site Number : 6160002, Wroclaw

90-127

Investigational Site Number : 6160011, Lodz

90-436

Investigational Site Number : 6160001, Lodz

00-874

Investigational Site Number : 6160007, Warsaw

02-758

Investigational Site Number : 6160005, Warsaw

89-600

Investigational Site Number : 6160003, Chojnice

80-546

Investigational Site Number : 6160004, Gdansk

40-040

Investigational Site Number : 6160009, Katowice

90-302

Investigational Site Number : 6160010, Lodz

02841

Investigational Site Number : 4100004, Seongbuk-Gu

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Kymera Therapeutics, Inc.

INDUSTRY

lead

Sanofi

INDUSTRY

NCT06058156 - Phase 2 Study of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis | Biotech Hunter | Biotech Hunter